RAF1 and cancer: AZ628, a type II selective pan-RAF kinase inhibitor, inhibits the activity of preactivated b-RAF, b-RAF V600E and c-RAF, blocking MEK activation and sustaining sensitivity to the MEK inhibitor, thus resulting in cancer cell proliferation inhibition [19, 23, 24].